Compared side by side
Retatrutide vs orforglipron: how they differ
The short answer
Orforglipron acts on one receptor, GLP-1, and is a small molecule (not a peptide) taken as a daily tablet; retatrutide is a weekly shot that activates three, GLP-1, GIP and glucagon. Orforglipron is FDA-approved, as Foundayo since April 2026, and retatrutide isn’t approved yet. In their own trials, orforglipron’s top dose averaged about 11% weight loss at 72 weeks, and retatrutide’s top dose about 25–28% at 80 weeks in phase 3.
Side by side
| Compared | Retatrutide | Orforglipron |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | LY3437943 | Foundayo, LY3502970, Orfo |
| What it is | The first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice). | A GLP-1 drug in a once-daily tablet that is not a peptide, so it comes with no fasting or water rules: Lilly's Foundayo, FDA-approved in April 2026 for weight management. |
| How it works | Triple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one. | Small-molecule (non-peptide) GLP-1 receptor agonist taken as a daily tablet. Because it is a small molecule it is absorbed without the fasting and water rules of oral semaglutide: the label puts its absolute bioavailability at 77% and lets it be taken with or without food. It reduces food intake, likely by lowering appetite, and delays stomach emptying, most after the first dose; in animal studies it reached and activated brain regions that regulate appetite. FDA-approved on April 1, 2026, as Foundayo for chronic weight management, at 0.8 to 17.2 mg once daily. |
| Commonly reported | Appetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet. | The easy routine is the main draw, with nausea, constipation or burping mostly in the weeks after each step-up. Its top dose averaged about 11% weight loss at 72 weeks in its main trial. |
| Studied range | Research range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation. | FDA label: 0.8–17.2 mg, starting dose 0.8 mg. |
| How often | Weekly | Daily |
| Half-life | ~6 days (measured in early trials in people) | ~29–49 hours (FDA label; steady levels after about a week of daily tablets) |
| Route | SubQ injection | Oral tablet |
| Typical run | Phase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration. | FDA-approved for long-term use alongside diet and activity. ATTAIN-MAINTAIN tested it as the follow-on to weekly injections for keeping weight off. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain | Nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping |
- Category
- RetatrutideMetabolic & GLP-1
- OrforglipronMetabolic & GLP-1
- Also known as
- RetatrutideLY3437943
- OrforglipronFoundayo, LY3502970, Orfo
- What it is
- RetatrutideThe first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice).
- OrforglipronA GLP-1 drug in a once-daily tablet that is not a peptide, so it comes with no fasting or water rules: Lilly's Foundayo, FDA-approved in April 2026 for weight management.
- How it works
- RetatrutideTriple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one.
- OrforglipronSmall-molecule (non-peptide) GLP-1 receptor agonist taken as a daily tablet. Because it is a small molecule it is absorbed without the fasting and water rules of oral semaglutide: the label puts its absolute bioavailability at 77% and lets it be taken with or without food. It reduces food intake, likely by lowering appetite, and delays stomach emptying, most after the first dose; in animal studies it reached and activated brain regions that regulate appetite. FDA-approved on April 1, 2026, as Foundayo for chronic weight management, at 0.8 to 17.2 mg once daily.
- Commonly reported
- RetatrutideAppetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet.
- OrforglipronThe easy routine is the main draw, with nausea, constipation or burping mostly in the weeks after each step-up. Its top dose averaged about 11% weight loss at 72 weeks in its main trial.
- Studied range
- RetatrutideResearch range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation.
- OrforglipronFDA label: 0.8–17.2 mg, starting dose 0.8 mg.
- How often
- RetatrutideWeekly
- OrforglipronDaily
- Half-life
- Retatrutide~6 days (measured in early trials in people)
- Orforglipron~29–49 hours (FDA label; steady levels after about a week of daily tablets)
- Route
- RetatrutideSubQ injection
- OrforglipronOral tablet
- Typical run
- RetatrutidePhase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration.
- OrforglipronFDA-approved for long-term use alongside diet and activity. ATTAIN-MAINTAIN tested it as the follow-on to weekly injections for keeping weight off.
- Evidence
- RetatrutideEstablished: clinical trials or FDA-approved use exists
- OrforglipronEstablished: clinical trials or FDA-approved use exists
- Common side effects
- RetatrutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain
- OrforglipronNausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Retatrutide
- Day 1–28 · 2 mg Triple-agonist is kicking in
- Day 29–84 · 4 mg Dose-response steepens
- Day 60+ · 9 mg Watch for dysesthesia at higher doses
- Day 84+ This is a maintenance medication, not a course
- Day 85–168 · 8 mg Higher steps: strong satiety
- Day 169–336 No plateau yet at week 48
- Day 337–476 Phase 3 territory: the headline numbers
Orforglipron
- Day 1–30 · 0.8 mg The 0.8 mg start
- Day 31–60 · 2.5 mg 2.5 mg, the second step
- Day 61+ · 5.5 mg 5.5 mg, the first maintenance dose
- Day 91+ · 9 mg 9 mg, an optional step
- Day 121+ · 14.5 mg 14.5 mg, the step before the top
- Day 151+ · 17.2 mg 17.2 mg, the top dose
Questions people ask
How long do retatrutide and orforglipron last?
The half-life of retatrutide is ~6 days (measured in early trials in people). The half-life of orforglipron is ~29–49 hours (FDA label; steady levels after about a week of daily tablets).
How often are retatrutide and orforglipron taken?
Retatrutide: weekly. Route: SubQ injection. Orforglipron: daily. Route: Oral tablet.
How are retatrutide and orforglipron dosed in research?
The research range for retatrutide is 1–12 mg, with a 2 mg starting dose. Studied in research — not a recommendation. The FDA label range for orforglipron is 0.8–17.2 mg, with a 0.8 mg starting dose.
What are the common side effects of retatrutide and orforglipron?
For retatrutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain. For orforglipron: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping.